21,892 results match your criteria Urticaria


Treatments of Cold Urticaria: A Systematic Review.

J Allergy Clin Immunol 2019 Feb 15. Epub 2019 Feb 15.

Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address:

Background: Several treatment options for cold urticaria (ColdU) have been studied and reported, but systematic reviews and meta-analyses are limited.

Objectives: To meta-analyze and review the efficacy and safety of ColdU treatments.

Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2019.02.005DOI Listing
February 2019

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.

J Asthma Allergy 2019 25;12:43-58. Epub 2019 Jan 25.

Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA.

Purpose: Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to describe the characteristics and associated economic burden of patients considered to be candidates for mepolizumab or omalizumab therapy.

Methods: This retrospective cohort study investigated patients with asthma (≥12 years of age) identified at the time of first mepolizumab or omalizumab administration (index date) in the MarketScan Commercial Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S189676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354698PMC
January 2019

Exercise-induce anaphylaxis, food-dependent exercise-induce anaphylaxis, cholinergic urticaria and Kounis syndrome.

Neth J Med 2019 Jan;77(1):38-39

Department of Cardiology, University of Patras Medical School, Rion, Patras, Achaia, Greece.

View Article

Download full-text PDF

Source
January 2019

Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review.

Int J Pediatr Otorhinolaryngol 2019 Jan 28;120:68-72. Epub 2019 Jan 28.

Division of Pediatric Rheumatology, Department of Pediatrics, IWK Health Centre, 5850/5980 University Ave, PO Box 9700, Halifax, NS, B3K 6R8, Canada. Electronic address:

Infant-onset bilateral sensorineural hearing loss is a key presenting symptom of the autoinflammatory cryopyrin-associated periodic syndrome. Other symptoms include periodic fever, cold-induced urticaria-like rash, chronic aseptic meningitis, polyarticular arthralgias, and renal AA amyloidosis. Early recognition and treatment with interleukin-1 blockade are critical for preventing disabling or fatal complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijporl.2019.01.037DOI Listing
January 2019

Does angioedema influence the quality of life in chronic spontaneous urticaria patients?

Ann Allergy Asthma Immunol 2019 Feb 12. Epub 2019 Feb 12.

Department of Internal Diseases, Allergology and Clinical Immunology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland; Department of Internal Diseases and Allergology, Institute of Medicine, University of Opole, Opole, Poland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2019.01.023DOI Listing
February 2019

Trends in hospitalizations related to anaphylaxis, angioedema and urticaria in the United States.

Ann Allergy Asthma Immunol 2019 Feb 12. Epub 2019 Feb 12.

Division of Pulmonary, Allergy and Critical Care Medicine, Penn State College of Medicine, Hershey, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2019.02.003DOI Listing
February 2019

Bloodletting therapy for treating patients with chronic urticaria: A systematic review and meta-analysis protocol.

Medicine (Baltimore) 2019 Feb;98(7):e14541

Beijing University of Chinese Medicine, Beijing, China.

Background: Chronic urticaria is a common disease affecting patients' quality of life, and leading to substantial burden to both patients and society. Many trials have shown that bloodletting therapy is effective in treating chronic urticaria. There are currently no systematic reviews of bloodletting therapy for chronic urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014541DOI Listing
February 2019

Biologic-induced urticaria due to polysorbate 20.

J Dermatol 2019 Feb 13. Epub 2019 Feb 13.

Department of Dermatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14808DOI Listing
February 2019

Intravenous immunoglobulin treatment: Where do dermatologists stand?

Authors:
Selma Emre

Dermatol Ther 2019 Feb 13:e12854. Epub 2019 Feb 13.

Department of Dermatology, Yildirim Beyazit University, Medical School, Ankara, Turkey.

Intravenous immunoglobulins are therapeutic products, comprising polyclonal IgGs, which are obtained from human plasma pool of healthy blood donors. Despite the lack of FDA approval, the experience of using IVIG in various dermatological diseases increases day by day and exciting results are reported. However, experience with the use of IVIG in dermatological indications are mostly case reports whereas randomized, controlled, double-blind, multicentric studies have not been performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12854DOI Listing
February 2019

The role of patient-reported outcomes in the management of chronic spontaneous urticaria.

Authors:
Kate Hopkinson

Br J Nurs 2019 Feb;28(3):144-150

Allergy Nurse Specialist, Department of Clinical Immunology and Allergy, Nottingham University Hospitals NHS Trust.

Chronic spontaneous urticaria (CSU) is a debilitating condition that can substantially affect patients' quality of life (QoL), mental health and ability to perform daily tasks. International guidelines on the management of CSU, jointly developed by the European Academy of Allergy and Clinical Immunology (EAACI), Global Allergy and Asthma European Network (GALEN), European Dermatology Forum (EDF) and World Allergy Organization (WAO), recommend a treat-to-target strategy until symptom control or remission is achieved. This may mean stepping up or down in the treatment algorithm according to the course of CSU and re-evaluating the need for continued/alternative drug treatment. Read More

View Article

Download full-text PDF

Source
http://www.magonlinelibrary.com/doi/10.12968/bjon.2019.28.3.
Publisher Site
http://dx.doi.org/10.12968/bjon.2019.28.3.144DOI Listing
February 2019
2 Reads

The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience.

Open Access Maced J Med Sci 2019 Jan 28;7(2):259-263. Epub 2019 Jan 28.

University of Rome G. Marconi, Rome, Italy.

Background: Chronic urticaria, a mast cell-driven condition, is common, debilitating and hard to treat. H1-antihistamines are the first line treatment of chronic urticaria, but often patients do not get satisfactory relief with the recommended dose. European guidelines recommend increased antihistamine doses up to four-fold. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3889/oamjms.2019.069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364734PMC
January 2019
1 Read

Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment.

J Neurol 2019 Feb 9. Epub 2019 Feb 9.

Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Centre National de Référence Maladies Systémiques Rares, Hôpital Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75651, Paris Cedex 13, France.

Objectives: Infliximab is increasingly used to treat neurosarcoidosis. We aimed to determine the efficacy and tolerance of an infliximab biosimilar for treating neurosarcoidosis.

Methods: We conducted a retrospective single-center study to describe the efficacy, safety and immunogenicity of an infliximab biosimilar in neurosarcoidosis patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-019-09234-yDOI Listing
February 2019
1 Read

Sense of coherence in selected allergic diseases.

Wiad Lek 2018 ;71(9):1774-1776

Department Of Psychiatry In Tarnowskie Gory, School Of Medicine With The Division Of Dentistry In Zabrze, Medical University Of Silesia, Zabrze, Polska.

According to "holistic" model of physician's approach to the patient, physical, psychological and social aspects should be taken into account when we assess disease and effects of diagnostics and treatment. Those attributes form health related quality of life. Patient's disposition to disease depends on many psychological factors, among them sense of coherence (SOC). Read More

View Article

Download full-text PDF

Source
January 2018
1 Read

GSK2646264, a spleen tyrosine kinase inhibitor attenuates the release of histamine in ex vivo human skin.

Br J Pharmacol 2019 Feb 8. Epub 2019 Feb 8.

Respiratory TAU, GSK, Gunnels Wood Rd, Stevenage.

Background And Purpose: Chronic Spontaneous Urticaria presents as a heterogeneous syndrome characterised by wheals, angioedema or both for greater than six weeks. Spleen tyrosine kinase (SYK) mediates allergen-induced mast cell degranulation via the IgE signalling pathway, a central component of wheal formation and inflammation. In this study, we demonstrate that perfused or topically administered GSK2646264 dose dependently attenuates IgE-mediated histamine release from mast cells in an ex vivo human skin model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.14610DOI Listing
February 2019
1 Read

The response to treatment in chronic spontaneous urticaria depends on how it is measured.

J Allergy Clin Immunol Pract 2019 Feb 4. Epub 2019 Feb 4.

Dept. of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.048DOI Listing
February 2019
1 Read

[Chilean guidelines for chronic urticaria].

Rev Med Chil 2018 Nov;146(11):1334-1342

Departamento de Dermatología, Facultad de Medicina, Universidad de Chile, Santiago, Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4067/S0034-98872018001101334DOI Listing
November 2018
1 Read

Omalizumab for atopic dermatitis: evidence for and against its use.

G Ital Dermatol Venereol 2019 Feb 4. Epub 2019 Feb 4.

Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.

Introduction: Omalizumab, has been used for almost two decades, mainly in allergic asthma and chronic spontaneous urticaria for which it is highly beneficial. Smaller studies have evaluated the effects of omalizumab in atopic dermatitis (AD). Current treatments options, such as cyclosporine and azathioprine have limited effect on AD and numerous side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06302-8DOI Listing
February 2019
1 Read

Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine.

G Ital Dermatol Venereol 2019 Feb 4. Epub 2019 Feb 4.

Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain -

The second-generation H1-antihistamines (sgAH) are the first-line symptomatic treatment of patients with chronic spontaneous urticaria (CSU). Up to 50% of the patients will not respond to licensed doses of sgAH. According to the guidelines, the dose of sgAH may be increased up to 4 times the conventional dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06274-6DOI Listing
February 2019
1 Read

Presentation and natural history of progestogen hypersensitivity.

Ann Allergy Asthma Immunol 2019 Feb 26;122(2):156-159. Epub 2018 Oct 26.

Jeff and Penny Vinik Center for Allergic Diseases Research, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

Objective: To review the published medical literature on the clinical presentation, risk factors, and natural history of hypersensitivity reactions to progestogens.

Data Sources: Through the use of PubMed, we conducted a review of allergy, dermatology, and obstetric literature for cases and case series of patients with hypersensitivity reactions to exogenous or endogenous progestogens. There are no longitudinal, prospective studies related to progestogen hypersensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anai.2018.10.023DOI Listing
February 2019
1 Read

H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria.

J Allergy Clin Immunol Pract 2019 Jan 29. Epub 2019 Jan 29.

Department of Dermatology and Allergy, Allergie-Centrum Charité, Charité -Universitätsmedizin Berlin, Berlin, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.030DOI Listing
January 2019
1 Read

Drug-induced anaphylactic reactions in children: A retrospective analysis of 159 validated spontaneous reports.

Pharmacoepidemiol Drug Saf 2019 Jan 31. Epub 2019 Jan 31.

Research Division, Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany.

Purpose: The main objective of this study was to analyze validated cases of drug-induced anaphylactic reactions in children with regard to incriminated drugs, clinical characteristics, and associated factors. A further objective was to compare differences in incriminated drugs and characteristics between validated cases and a reference excluding anaphylactic reaction cases (basic dataset).

Methods: Spontaneous reports of anaphylactic reactions in children (0-17 years) registered between January 2000 to December 2016 were extracted from the adverse drug reaction database of the German Federal Institute for Drugs and Medical Devices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pds.4726DOI Listing
January 2019
1 Read

Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).

Health Qual Life Outcomes 2019 Jan 31;17(1):23. Epub 2019 Jan 31.

Allergy Unit, Pneumology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Background: The daily diary Urticaria Activity Score (UAS) and its weekly score (UAS7) are widely used to assess signs and symptoms in patients with chronic spontaneous urticaria (CSU). The objective of this study was to assess the psychometric properties of a Spanish version of the once-daily UAS.

Methods: Observational study in patients ≥18 years old receiving usual care for CSU (daily or almost daily occurrence of generalized hives or angioedema for ≥6 weeks). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12955-019-1087-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357477PMC
January 2019
1 Read

The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study).

Eur J Dermatol 2018 Dec;28(6):795-802

Hospices civils de Lyon, Claude-Bernard University, Lyon, France.

Data on the clinical burden of chronic spontaneous urticaria (CSU) and economic consequences are lacking in France. To characterize the clinical and economic burden of CSU in symptomatic patients despite treatment by analysing data of French patients from the ASSURE-CSU study. ASSURE-CSU was an international observational study that included CSU patients with symptoms that lasted for 12 months or more despite treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3446DOI Listing
December 2018
1 Read

Incidental Pharmacogenetics Findings in an HLA-related Research: Considerations for Primary Prevention.

Clin Exp Allergy 2019 Jan 28. Epub 2019 Jan 28.

Faculty of Medicine, Universiti Kuala Lumpur Royal College of Medicine Perak, Ipoh, Perak, Malaysia.

Hypersensitivity drug reactions (HDRs) are an immense public health problem where significant proportions may lead to mortality. HDRs can manifest in various phenotypes, mainly cutaneous reactions that range from the mild; i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cea.13347DOI Listing
January 2019
8 Reads
4.769 Impact Factor

Eosinophilic infiltration: an under-reported histological finding in urticarial vasculitis.

Int J Dermatol 2019 Jan 28. Epub 2019 Jan 28.

Autoimmune Bullous Disease Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Background: Urticarial vasculitis (UV) is a clinicopathologic entity in which skin lesions resemble urticaria clinically but last more than 24 hours and resolve with residual purpura. In this study, we evaluated distinguishing histological features of UV from common urticaria to differentiate between these two entities.

Methods: During 1 year, 55 urticaria and 245 UV samples were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14387DOI Listing
January 2019
1 Read
1.227 Impact Factor

New Insights into the Utility of Omalizumab.

J Allergy Clin Immunol 2019 Jan 25. Epub 2019 Jan 25.

Department of Internal Medicine, Division of Allergy and Immunology at the Morsani College of Medicine of the University of South Florida in Tampa, FL. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2019.01.016DOI Listing
January 2019
1 Read

Headache deteriorates the quality of life in children with chronic spontaneous urticaria.

Allergol Immunopathol (Madr) 2019 Jan 24. Epub 2019 Jan 24.

Akdeniz University, Department of Pediatric Allergy and Immunolgy, Antalya, Turkey.

Background: Quality of life, which is impaired in patients with chronic spontaneous urticaria (CSU), is influenced by comorbid mental disorders. Headaches could be another comorbid mental disorder that affects quality of life in children with CSU.

Objectives: To investigate the effect of headaches on urticaria symptoms, disease activity and quality of life in children with CSU. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.aller.2018.09.002DOI Listing
January 2019
1 Read

Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.

J Allergy Clin Immunol Pract 2019 Jan 25. Epub 2019 Jan 25.

Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Electronic address:

Background: The high-affinity IgE receptor (FcεRI) expression on effector cells has been poorly characterized in patients with chronic urticaria (CU) to date.

Objectives: To investigate the FcεRI expression on blood basophils in a large cohort of patients with CU and its potential relationship with relevant features of the disease.

Methods: Basophil FcεRI expression was measured by flow cytometry in 287 patients with CU (192 with chronic spontaneous urticaria and 95 with chronic inducible urticaria) at their initial evaluation in our department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.026DOI Listing
January 2019
2 Reads

Vaccine Allergy? Skin testing and challenge at a tertiary pediatric hospital in Melbourne, Australia.

J Allergy Clin Immunol Pract 2019 Jan 22. Epub 2019 Jan 22.

Department of Allergy & Immunology, Royal Children's Hospital, Melbourne, Australia; Food Allergy Research Group and Melbourne Children's Trial Centre, Murdoch Children's Research Institute, Melbourne, Australia; Department of General Medicine, Royal Children's Hospital, Melbourne, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.

Background: The rate of true vaccine allergy is unknown. Children with potential IgE-mediated Adverse Events Following Immunization (AEFI) should undergo allergy investigation that may include skin testing or challenge. Previous protocols tend to be highly conservative and often suggest invasive testing for all; a practice not evidence based, technically difficult and unpleasant in children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.01.025DOI Listing
January 2019
6 Reads

Progesterone hypersensitivity: Case report with favorable evolution.

Exp Ther Med 2019 Feb 5;17(2):1125-1127. Epub 2018 Dec 5.

Department of Psychiatry, Clinical Hospital of Psychiatry 'Al. Obregia', 041914 Bucharest, Romania.

Progesterone hypersensitivity or autoimmune progesterone dermatitis is characterized by heterogeneous skin eruptions that cyclically aggravate during the second half of the menstrual cycle, corresponding to a rise in the progesterone level. Clinical presentation is highly variable and includes all urticaria manifestations with or without angioedema, vesiculobullous, eczematous, purpuric or target-like lesions on the skin and mucous membrane. Both endogenous progesterone as well as exogenous progestogens may represent an initial trigger. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7055DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327669PMC
February 2019
1 Read

The incidence of skin lesions in contrast media-induced chemical hypersensitivity.

Exp Ther Med 2019 Feb 5;17(2):1113-1124. Epub 2018 Dec 5.

Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Contrast agents are used in radiology to increase the sensibility and specificity of radiological techniques. Some of these compounds have side effects that include organ toxicity (with kidney being the most affected organ) and hypersensitivity reactions. We performed multiple PubMed searches from January, 2008 to January, 2018 for studies regarding adverse reactions to compounds used as contrast agents in imagistic techniques. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327547PMC
February 2019
1 Read

Isolated angioedema: An overview of clinical features and etiology.

Exp Ther Med 2019 Feb 16;17(2):1068-1072. Epub 2018 Nov 16.

Allergology and Immunology Discipline, 'Iuliu Hațieganu' University of Medicine and Pharmacy, Cluj-Napoca 400012, Romania.

Angioedema can occur in isolation, accompanied by urticaria, or as a feature of anaphylaxis in mast cell-mediated disorders, bradykinin-mediated disorders, as well as in others with unknown mechanisms, such as infections, rare disorders, or idiopathic angioedema. In mast cell-mediated angioedema, other signs and symptoms of mast cell-mediator release are frequently seen. However, clear evidence of mast cell degranulation may be absent in histaminergic angioedema. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327642PMC
February 2019
1 Read

Advances in the pathogenesis representing definite outcomes in chronic urticaria.

Curr Opin Allergy Clin Immunol 2019 Jan 22. Epub 2019 Jan 22.

Universidad de Antioquia, Colombia.

Purpose Of Review: We reviewed in this article, the recent advances in CSU physiopathology and potential clinical and laboratory biomarkers in CSU.

Recent Findings: In addition to the central role of mast cells in urticaria physiopathology, increased interest in basophils has arisen. Recent data corroborate the autoimmunity pathway as one of the main pathways in mast cell activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ACI.0000000000000519DOI Listing
January 2019
3 Reads

IgE-mediated sensitization to galactose-alpha-1,3-galactose (α-gal) in urticaria and anaphylaxis in Spain: geographical variations and risk factors.

J Investig Allergol Clin Immunol 2019 Jan 24. Epub 2019 Jan 24.

Allergy Unit, Pneumology Department, Hospital Clinic, Barcelona, Spain.

Background: The aims of this study were to investigate the prevalence of sIgE to galactose-alpha-1,3-galactose (α-gal) in individuals with acute urticaria or anaphylaxis from different geographical areas of Spain and to evaluate the relevance of demographics and lifestyle as risk factors for this immune response.

Methods: Participants were recruited from allergy departments at 14 Spanish hospitals. Patients aged 18 years or older presenting with urticaria or anaphylaxis were enrolled into one of two arms: cases and controls. Read More

View Article

Download full-text PDF

Source
http://www.jiaci.org/ahead-of-print/ige-mediated-sensitizati
Publisher Site
http://dx.doi.org/10.18176/jiaci.0373DOI Listing
January 2019
5 Reads

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report.

Allergy Asthma Clin Immunol 2019 17;15. Epub 2019 Jan 17.

3Department of Medicine, Western University, London, ON Canada.

Background: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been described; however, their relationship to the drug remains uncertain, and the frequency is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13223-019-0319-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337756PMC
January 2019
1 Read

[Experience in the treatment of difficult diseases by technical combination of acupuncture].

Authors:
Lai-Xi Ji

Zhongguo Zhen Jiu 2019 Jan;39(1):73-6

Shanxi University of CM, Taiyuan 030619, China.

The technical combination of acupuncture is a combination therapy based on the purpose of improving clinical efficacy. After years of clinical practice, the author has gradually summarized the dominant disease spectrum of combination therapy, especially for the treatment of difficult diseases such as male and dermatological. In the treatment of chronic prostatitis, the combination of acupuncture at "Zhibian (BL 54) through Shuidao (ST 28) therapy" is adopted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13703/j.0255-2930.2019.01.016DOI Listing
January 2019
1 Read

Urticaria pigmentosa-like skin disease in a domestic shorthair cat.

JFMS Open Rep 2019 Jan-Jun;5(1):2055116918821197. Epub 2019 Jan 7.

Department of Clinical Medicine, University of Illinois Veterinary Teaching Hospital, Urbana, IL, USA.

Case Summary: A 14-month-old castrated male domestic shorthair cat presented with an 8 month history of severe pruritus, alopecia, papules and excoriations. Initial evaluation and treatment prior to referral included skin scrape, cytology, two strict food trials, dermatophyte culture, and bacterial culture and sensitivity, as well as antibiotic therapy, empiric treatment for mites, steroids and ciclosporin A (Atopica; Elanco). The cat was referred to the Dermatology and Otology Clinic at the University of Illinois Veterinary Teaching Hospital for further diagnostics and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2055116918821197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327337PMC
January 2019
1 Read

Traditional Uses, Botany, Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of L.: A Review.

Molecules 2019 Jan 19;24(2). Epub 2019 Jan 19.

School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.

L. (Asteraceae) is a common and well-known traditional Chinese herbal medicine usually named Cang-Er-Zi, and has been used for thousands of years in China. The purpose of this paper is to summarize the progress of modern research, and provide a systematic review on the traditional usages, botany, phytochemistry, pharmacology, pharmacokinetics, and toxicology of the . Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1420-3049/24/2/359
Publisher Site
http://dx.doi.org/10.3390/molecules24020359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359306PMC
January 2019
6 Reads
2.416 Impact Factor

Cytokines and soluble receptors of the interleukin-1 family in Schnitzler syndrome.

Scand J Rheumatol 2019 Jan 22:1-4. Epub 2019 Jan 22.

b Institute of Protein Biochemistry , National Research Council , Naples , Italy.

Objectives: Schnitzler syndrome (SchS) is an autoinflammatory disorder characterized by chronic urticaria, fever, and monoclonal gammopathy. The success of interleukin-1 (IL-1) blocking therapies suggests a crucial role for IL-1 in disease induction. The aim of this study is to perform a comprehensive analysis of IL-1 family cytokines and soluble receptors in a group of SchS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03009742.2018.1550210DOI Listing
January 2019
1 Read

Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti-inflammatory drug-induced urticarial.

Allergy 2019 Jan 22. Epub 2019 Jan 22.

ARADyAL Network RD16/0006/0001, Carlos III Health Institute, Madrid, Spain.

Background: The role of arachidonic acid metabolites in NSAID-induced hypersensitivity has been studied in depth for NSAID-exacerbated respiratory disease (NERD) and NSAID-exacerbated cutaneous disease (NECD). However, no information is available for NSAID-induced urticarial/angioedema (NIUA), despite it being the most frequent clinical entity induced by NSAID hypersensitivity. We evaluated changes in leukotriene and prostaglandin metabolites for NIUA patients, using patients with NECD and single-NSAID-induced urticaria/angioedema or anaphylaxis (SNIUAA) for comparison. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/all.13725
Publisher Site
http://dx.doi.org/10.1111/all.13725DOI Listing
January 2019
8 Reads

Efficacy of autologous whole blood or serum therapy for chronic spontaneous urticaria: A systematic review and meta-analysis.

J Dermatolog Treat 2019 Jan 21:1-28. Epub 2019 Jan 21.

a Department of Dermatology , Taipei Medical University Hospital , Taipei , Taiwan.

Background: Chronic spontaneous urticaria (CSU) is chronic wheals without identifiable exogenous stimuli. Autologous whole blood (AWB) injection and autologous serum therapy (AST) are alternative therapies for CSU that induce tolerance to circulating histamine-releasing factors.

Objective: We elucidated currently available evidence for the efficacy and safety of AWB therapy and AST for CSU. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1
Publisher Site
http://dx.doi.org/10.1080/09546634.2019.1572863DOI Listing
January 2019
8 Reads

Eperisone-Induced Anaphylaxis: Pharmacovigilance Data and Results of Allergy Testing.

Allergy Asthma Immunol Res 2019 Mar;11(2):231-240

Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Eperisone is an oral muscle relaxant used in musculoskeletal disorders causing muscle spasm and pain. For more effective pain control, eperisone is usually prescribed together with nonsteroidal anti-inflammatory drugs (NSAIDs). As such, eperisone may have been overlooked as the cause of anaphylaxis compared with NSAIDs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4168/aair.2019.11.2.231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340802PMC
March 2019
2 Reads

Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review.

Asian Pac J Allergy Immunol 2019 Jan 13. Epub 2019 Jan 13.

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Urticarial vasculitis (UV) is a rare form of cutaneous leukocytoclastic vasculitis with persistent urticarial lesions. UV may be severe and refractory to standard treatment including antihistamines, anti-inflammatories, antimalarials, corticosteroids and immunosuppressants. Omalizumab, an anti-IgE antibody, is approved for chronic spontaneous urticaria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12932/AP-050918-0402DOI Listing
January 2019
5 Reads

Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.

Dermatol Ther 2019 Jan 18:e12829. Epub 2019 Jan 18.

Dermatology and Venereology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain.

Bullous pemphigoid (BP) is an acquired autoimmune bullous disease characterized by autoantibodies against the hemidesmosomal proteins found in the basal keratinocytes of the basement membrane zone (BMZ): a 180 kDa protein (type XVII collagen) mainly and the 230 kDa antigen. There is such evidence that the antibodies against the BMZ components are not only of IgG type, but also this bullous disease may have IgE antibodies directed to the BMZ that contribute to the pathogenesis of the disorder. IgE is not only thought to contribute to the pathogenesis of BP, it has also been suggested that eosinophils play a role in the development of the first signs associated with BP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12829DOI Listing
January 2019
2 Reads

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007⁻2018.

Pharmacy (Basel) 2019 Jan 17;7(1). Epub 2019 Jan 17.

Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, 31-531 Krakow, Poland.

Paracetamol is a popular and easily available drug which is used world-wide as analgesic, antipyretic agent. Hypersensitivity reactions to this drug involve a wide range of symptoms of various importance for patient management. The EudraVigilance (EV) database serves as a system for monitoring adverse events (AE) due to drug intake. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/pharmacy7010012DOI Listing
January 2019
4 Reads

[Angioedema prophylaxis].

Authors:
V Zampeli M Magerl

Hautarzt 2019 Feb;70(2):107-115

Klinik für Dermatologie, Venerologie und Allergologie, Allergie-Centrum-Charité/ECARF, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

Angioedema is a spontaneous, edematous swelling of the deep layers of the skin or mucous membrane. Angioedema in the respiratory tract is potentially life-threatening. The classification of angioedema into mast-cell-mediated (e. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00105-018-4345-9
Publisher Site
http://dx.doi.org/10.1007/s00105-018-4345-9DOI Listing
February 2019
5 Reads

Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.

J Allergy Clin Immunol Pract 2019 Jan 15. Epub 2019 Jan 15.

Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain; RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL), Madrid, Spain. Electronic address:

Background: Cholinergic urticaria (UCOL) is a highly disabling inducible urticaria triggered by an increase in core body temperature.

Objective: To explore the safety and efficacy of omalizumab in controlling UCOL.

Methods: We conducted a multicenter randomized mixed double-blind and open-label (first 4 months blinded followed by 8 months open-label) placebo-controlled clinical trial in 22 patients suffering from UCOL who were unresponsive to a double dose of antihistamines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.12.025DOI Listing
January 2019
5 Reads